FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome
Stock Information for Athersys Inc.
Loading
Please wait while we load your information from QuoteMedia.